Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $215.0 million.

  • Indivior Pharmaceuticals' Accounts Payables rose 12638.04% to $215.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 12638.04%. This contributed to the annual value of $216.0 million for FY2024, which is 1076.92% up from last year.
  • As of Q3 2025, Indivior Pharmaceuticals' Accounts Payables stood at $215.0 million, which was up 12638.04% from $196.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Accounts Payables peaked at $720.0 million during Q4 2021, and registered a low of -$815.0 million during Q3 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' median Accounts Payables value was $189.0 million (recorded in 2023), while the average stood at -$119.9 million.
  • In the last 5 years, Indivior Pharmaceuticals' Accounts Payables crashed by 6839.55% in 2023 and then skyrocketed by 12638.04% in 2025.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Accounts Payables stood at $720.0 million in 2021, then decreased by 14.31% to $617.0 million in 2022, then tumbled by 68.4% to $195.0 million in 2023, then increased by 10.77% to $216.0 million in 2024, then decreased by 0.46% to $215.0 million in 2025.
  • Its Accounts Payables stands at $215.0 million for Q3 2025, versus $196.0 million for Q2 2025 and $183.0 million for Q1 2025.